CXCR4/CXCL12 blockade therapy; a new horizon in TNBC therapy.

Khaleel AQ, Altalbawy FMA, Jabir MS, F Hasan T, Jain V, Abbot V, Nakash P, Kumar MR, Mustafa YF, Jawad MA

Open source

DOI
10.1007/s12032-025-02705-5
Published
2025 Apr 11
Container
Medical oncology (Northwood, London, England)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s12032-025-02705-5,
  title = {CXCR4/CXCL12 blockade therapy; a new horizon in TNBC therapy.},
  author = {Khaleel AQ and Altalbawy FMA and Jabir MS and F Hasan T and Jain V and Abbot V and Nakash P and Kumar MR and Mustafa YF and Jawad MA},
  year = {2025},
  journal = {Medical oncology (Northwood, London, England)},
  doi = {10.1007/s12032-025-02705-5},
  url = {https://doi.org/10.1007/s12032-025-02705-5}
}

RIS

TY  - JOUR
TI  - CXCR4/CXCL12 blockade therapy; a new horizon in TNBC therapy.
AU  - Khaleel AQ
AU  - Altalbawy FMA
AU  - Jabir MS
AU  - F Hasan T
AU  - Jain V
AU  - Abbot V
AU  - Nakash P
AU  - Kumar MR
AU  - Mustafa YF
AU  - Jawad MA
PY  - 2025
JO  - Medical oncology (Northwood, London, England)
DO  - 10.1007/s12032-025-02705-5
UR  - https://doi.org/10.1007/s12032-025-02705-5
ER  - 

APA

AQ, K., FMA, A., MS, J., T, F. H., V, J., V, A., P, N., MR, K., YF, M., & MA, J. (2025). CXCR4/CXCL12 blockade therapy; a new horizon in TNBC therapy.. Medical oncology (Northwood, London, England). https://doi.org/10.1007/s12032-025-02705-5

Source records